MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clinbiochem.2012.12.019

Медицинская библиотека · Clinical biochemistry · 2013

Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.

Krastins Bryan, Prakash Amol, Sarracino David A, Nedelkov Dobrin, Niederkofler Eric E, Kiernan Urban A, Nelson Randall, Vogelsang Maryann S, Vadali Gouri, Garces Alejandra, Sutton Jennifer N, Peterman Scott, Byram Gregory, Darbouret Bruno, Pérusse Joëlle R, Seidah Nabil G, Coulombe Benoit, Gobom Johan, Portelius Erik, Pannee Josef, Blennow Kaj, Kulasingam Vathany, Couchman Lewis, Moniz Caje, Lopez Mary F

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

The aim of this study was to develop high-throughput, quantitative and highly selective mass spectrometric, targeted immunoassays for clinically important proteins in human plasma or serum.

DESIGN AND

METHODS

The described method coupled mass spectrometric immunoassay (MSIA), a previously developed technique for immunoenrichment on a monolithic microcolumn activated with an anti-protein antibody and fixed in a pipette tip, to selected reaction monitoring (SRM) detection and accurate quantification of targeted peptides, including clinically relevant sequence or truncated variants.

RESULTS

In this report, we demonstrate the rapid development of MSIA-SRM assays for sixteen different target proteins spanning seven different clinically important areas (including neurological, Alzheimer's, cardiovascular, endocrine function, cancer and other diseases) and ranging in concentration from pg/mL to mg/mL. The reported MSIA-SRM assays demonstrated high sensitivity (within published clinical ranges), precision, robustness and high-throughput as well as specific detection of clinically relevant isoforms for many of the target proteins. Most of the assays were tested with bona-fide clinical samples. In addition, positive correlations, (R2 0.67-0.87, depending on the target peptide), were demonstrated for MSIA-SRM assay data with clinical analyzer measurements of parathyroid hormone (PTH) and insulin growth factor 1 (IGF1) in clinical sample cohorts.

CONCLUSIONS

We have presented a practical and scalable method for rapid development and deployment of MS-based SRM assays for clinically relevant proteins and measured levels of the target analytes in bona fide clinical samples. The method permits the specific quantification of individual protein isoforms and addresses the difficult problem of protein heterogeneity in clinical proteomics applications.

Для цитирования: Krastins Bryan, Prakash Amol, Sarracino David A, Nedelkov Dobrin, Niederkofler Eric E, Kiernan Urban A, Nelson Randall, Vogelsang Maryann S, Vadali Gouri, Garces Alejandra, Sutton Jennifer N, Peterman Scott, Byram Gregory, Darbouret Bruno, Pérusse Joëlle R, Seidah Nabil G, Coulombe Benoit, Gobom Johan, Portelius Erik, Pannee Josef, Blennow Kaj, Kulasingam Vathany, Couchman Lewis, Moniz Caje, Lopez Mary F. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum.. Clinical biochemistry. 2013. DOI: 10.1016/j.clinbiochem.2012.12.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.